ReviewMolecular neurobiology2026
PIWI-piRNA Axis in Epilepsy: Bridging Epigenetic Regulation, Neuroinflammation, and Neuronal Excitability.
Review in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epilepsy is a chronic neurological disorder characterized by recurrent seizures, neuroinflammation, and epigenetic instability, with around one-third of patients experiencing drug-resistant epilepsy. While ion channels and neurotransmitter imbalances have been thoroughly examined in relation to epilepsy, the significance of piRNAs and their interaction with PIWI proteins in gene regulation, transposon silencing, and inflammatory signaling inside the epileptic brain is gaining recognition. This summary encapsulates the existing understanding of piRNA synthesis, the epigenetic control through PIWI-piRNA interactions, and their novel roles in epileptogenesis. PIWI-piRNA complexes target highly expressed genomic areas, such as LINE-1 retrotransposons, and mute them by recruiting chromatin modifiers such DNMT3A and H3K9 methyltransferase complexes, therefore influencing genome stability and neuronal excitability. Additionally, piRNAs initiate pathways associated with neuroinflammation, including the activation of the Toll-like receptor-4/NF-kB signaling pathway and the NLRP3 inflammasome, and indirectly influence GABAergic homeostasis through interactions with the extensive noncoding RNA regulatory network. Targeted modulation of kainic acid, pilocarpine, and hereditary epilepsy models has been documented to provide decreases in seizure load; however, the extent of this effect varies among the models and modulation techniques employed. The review critically evaluates emerging therapeutic strategies, including AAV9 vectors, lipid nanoparticles, exosome-based delivery systems, and antisense oligonucleotides, along with their associated challenges such as blood-brain barrier penetration, off-target effects, immune activation, and long-term safety. In conclusion, the PIWI-piRNA axis represents a potential yet nascent domain for biomarker creation and disease modulation in epilepsy.
Indexed as
Identifiers
42572073What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.